Meeting
2022 ASCO Annual Meeting
Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non–small cell lung cancer treated at Veterans Health Administration facilities.
Authors
Amanda Moore
College of Pharmacy, The University of Texas at Austin, Austin, TX
Amanda Moore , Zohra Nooruddin , Kelly R Reveles , Paromita Datta , Lance Brannman , Ion Cotarla , Andrew Frankart , Tiernan Mulrooney , Xavier Jones , Christopher R Frei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8526)
DOI
10.1200/JCO.2022.40.16_suppl.8526
Abstract #
8526
Poster Bd #
153
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Durvalumab treatment initiation delays in patients with unresectable stage III non–small cell lung cancer treated at Veterans Health Administration facilities.
First Author: Paromita Datta
Poster
2023 ASCO Quality Care Symposium
Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ.
First Author: Daniel P. Petro
Poster
2023 ASCO Annual Meeting
A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Luis G. Paz-Ares
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu